🔗 Permalink

Inventor profile of:

Michael Hayden

City:

Petach-Tikva

Country:

Israel

Published Applications:

Last publication date:

2019-04-25

Top Assignees for applications by Michael Hayden

The entities that hold a legal rights for patent applications filed by inventor Hayden Michael:

Teva Pharmaceutical Industries, Ltd. 15 Petach-Tikva, Israel
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. 2 Jerusalem, Israel
Teva Pharmaceuticals International GmbH 2 Jona, Switzerland
Prilenia Neurotherapeutics Ltd. 2 Herzliya, Israel
The Board of Regents of the University of Texas System 1 Austin, TX United States
TEVA PHARMACEUTICALS INDUSTRIES LTD. 1 Petach-Tikva, Israel

Recent patent applications by Hayden Michael

Michael Hayden from Petach-Tikva, IL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-04-25

US20190117639A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#2 | 2019-01-03

US20190000854A1

Human necessities

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

#3 | 2018-12-27

US20180369228A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#4 | 2018-09-06

US20180250285A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#5 | 2018-05-17

US20180133209A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#6 | 2018-03-01

US20180055832A1

Human necessities

Use of pridopidine for treating functional decline

#7 | 2018-01-04

US20180002753A1

Chemistry; metallurgy

GENETIC MARKERS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE

#8 | 2017-12-14

US20170354651A1

Human necessities

Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod

#9 | 2017-11-09

US20170319569A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#10 | 2017-08-10

US20170224674A1

Human necessities

Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod

#11 | 2017-04-20

US20170105996A1

Human necessities

TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE

#12 | 2017-01-05

US20170003277A1

Physics

BIOLOGICAL CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED DRUG PRODUCT USING MAMMALIAN AND HUMAN CELLS

#13 | 2016-10-27

US20160312284A1

Chemistry; metallurgy

SELECT SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE

#14 | 2016-08-25

US20160243098A1

Human necessities

Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

#15 | 2016-03-17

US20160074380A1

Human necessities

Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod

#16 | 2015-08-06

US20150216850A1

Human necessities

COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#17 | 2015-07-30

US20150209346A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#18 | 2015-04-23

US20150110733A1

Human necessities

Genetic markers predictive of response to glatiramer acetate

#19 | 2014-03-27

US20140088145A1

Human necessities

COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

#20 | 2014-03-27

US20140088140A1

Human necessities

COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE

InventorID:

705102 ⎘